From MD to FDA Commissioner to CEO: Stephen Hahn Brings Every Perspective on Science, Policy, and Business

Healthcare innovation is often framed as a scientific challenge — the assumption being that if science advances fast enough, better outcomes will follow. After decades spent moving between nearly every major stakeholder group in the industry, Stephen Hahn has reached a different conclusion.

Few people have seen the innovation ecosystem from as many angles. Before becoming CEO of Nucleus RadioPharma, Hahn served as Commissioner of the FDA, Chief Medical Executive of MD Anderson Cancer Center, a practicing oncologist and clinical investigator, and Chief Medical Officer at Flagship Pioneering, the venture creation firm behind Moderna. Each role exposed him to different incentives and definitions of success — and together, they revealed a pattern: healthcare rarely struggles from a shortage of scientific ideas. It struggles because turning those ideas into patient impact means navigating a fragmented system that was never designed to move in alignment.

“The science enables,” Hahn said. “The real difficulty is taking that science, translating it into something that can help solve a significant problem for humankind, and ultimately turning it into something patients can actually access.”

Discovery, in other words, isn’t the finish line. It’s the starting point.

Healthcare’s Greatest Challenge Is Translation, Not Discovery

Innovation in biotech is usually discussed through the lens of breakthroughs — new targets, novel modalities, gene editing, radiopharmaceuticals, AI, precision medicine. Yet many promising technologies never reach patients, and many approved ones fail to reach their full potential. Hahn believes the explanation lies in the spaces between disciplines.

Scientists understand biology. Clinicians understand disease. Regulators understand evidence. Investors understand risk. Manufacturers understand scale. Health systems understand implementation. Each group plays its role well, but each operates under different incentives and timelines — and innovation often slows not because any single stakeholder fails, but because the connections between them are weak.

Hahn has watched discoveries stall at every stage: some fail to secure funding despite strong science, others hit unexpected regulatory hurdles, still others win approval but struggle with reimbursement, adoption, or manufacturing scale. The science may stay strong while the path to impact fragments around it.

“I don’t think everybody should be an academic physician, a regulator, and an industry executive,” Hahn said, laughing. “That’s a lot of hats to wear.” Still, he sees understanding multiple stakeholder perspectives as one of the most overlooked skills in successful innovation.

That lesson crystallized during his years in academic oncology. Institutions like MD Anderson operate at the research frontier, but most patients are treated elsewhere. “Eighty percent of cancer patients are treated in the community,” he noted — a reality that reframes how innovation should be judged. A breakthrough that succeeds at a major academic center but can’t be deployed in community settings has only solved part of the problem. Innovation has to be built for the system patients actually experience.

Why Commercialization Is Not the Opposite of Patient Care

One of Hahn’s sharper observations concerns the relationship between science and commercialization. In some academic circles, business activity is still viewed with suspicion, as if commercial goals and patient benefit sit in tension. Hahn rejects that framing entirely — commercialization, in his view, is one of the mechanisms that lets innovation reach patients at scale.

A lab discovery doesn’t improve outcomes simply by existing. A journal publication doesn’t change clinical practice on its own. Even positive trial results are just one stage in a much longer process — manufacturing, regulatory submissions, quality systems, reimbursement, distribution, and physician education all require heavy investment before a product ever reaches a patient.

“There has traditionally been a view in some academic environments that industry represents the dark side,” Hahn said. “But the reality is that if you want a product to help people at scale, somebody has to invest in developing it.”

This is one of healthcare’s enduring tensions: the industry is mission-driven, yet bringing a therapy to market can cost hundreds of millions or billions of dollars over a decade or more, with most candidates failing along the way. Without investors absorbing that risk, many transformative technologies would never leave the lab. “People over profit is important,” Hahn said. “But products don’t get developed without investors willing to take risks.” For him, the real challenge isn’t choosing between patients and business — it’s building systems where commercial incentives and patient outcomes reinforce each other.

Why Regulators Are Often Misunderstood

Few stakeholders generate more anxiety in biotech than regulators. Founders worry about delays, investors worry about uncertainty, scientists worry about complications to their development plans. Having served as FDA Commissioner, Hahn has watched these concerns from both sides of the table, and his advice is consistent: “Talk to regulators early and often.”

Many companies delay engagement, fearing difficult feedback or assuming they should wait until programs mature. Hahn argues this often increases risk rather than reducing it. “You’re going to hear it eventually,” he said. “The question is whether you hear it now and can plan for it, or whether you hear it after you’ve already invested years of work and capital.”

A broader theme runs through this: the distinction between risk and uncertainty. Risk can be modeled and priced in; uncertainty is far harder to manage. The clearer a regulatory pathway becomes, the easier it is for companies to attract capital and plan long term — making regulatory clarity not just a compliance matter, but an innovation catalyst. Even demanding requirements are navigable if they’re transparent; it’s ambiguity that creates hesitation across the ecosystem.

Antimicrobial Resistance Is Exposing a Failure of Innovation Economics

Few challenges concern Hahn more than antimicrobial resistance. “I am very scared of antimicrobial resistance,” he said bluntly. The concern isn’t only biological — AMR exposes a deeper problem: the widening gap between public health priorities and market incentives.

Unlike oncology or chronic-disease therapies, successful antibiotics create an economic paradox — the more valuable a new antibiotic is, the more it should be conserved, since responsible stewardship means limiting use to preserve effectiveness and slow resistance. Clinically rational; commercially, a real problem. “If I’m an investor developing the next-generation antibiotic,” Hahn explained, “I already know it’s going to have a limited market because ideally we want to preserve it.”

The result is a textbook market failure: society urgently needs new antimicrobials, but conventional investment models can’t easily justify the economics. Hahn believes closing this gap requires policy innovation alongside scientific innovation — extended exclusivity periods, alternative reimbursement models, public-private partnerships, and procurement guarantees that reward products for societal value rather than sales volume. He also sees promise in non-traditional approaches like bacteriophage therapy. AMR is a case study in a broader truth: even when science can solve a problem, misaligned incentives can still block success.

Stephen Hahn’s Blueprint for Healthcare Innovation

Drawing on decades across clinical medicine, academic leadership, regulation, venture creation, and commercialization, Hahn’s observations form a consistent framework:

1. Start with the patient problem, not the technology. The most durable innovations begin with a clearly defined unmet need and work backward — technologies and platforms shift, but real patient problems don’t.
2. Understand the entire development pathway early. Regulatory, manufacturing, reimbursement, and adoption realities all shape whether a technology reaches patients. Understanding them early avoids costly surprises later.
3. Treat regulators as strategic partners. Early feedback creates flexibility; feedback that arrives after years of work creates delays. Clarity reduces the uncertainty that most discourages investment.
4. Recognize that commercialization is part of translation. Manufacturing, capital, reimbursement, and distribution aren’t separate from innovation — they’re what let a therapy reach enough patients to matter.
5. Align incentives with areas of greatest need. AMR shows that some urgent challenges can’t be solved by science alone; innovation follows incentives, so policy must make solving critical problems economically sustainable.
6. Define success through access. Breakthroughs, approvals, and launches are milestones, not conclusions — the real measure of innovation is whether patients can actually benefit from it.

The View From Every Side of the Table

What sets Hahn apart isn’t any single role he’s held, but how many he’s held. Few healthcare leaders have worked as a practicing oncologist, cancer center executive, regulator, venture builder, investor, and biotech CEO. Each vantage point exposes different constraints and incentives — together, they show how fragmented innovation becomes when stakeholders focus only on their own piece of the puzzle.

That experience has led Hahn to a conclusion that’s simple to state and hard to execute: healthcare innovation succeeds only when every part of the system moves in the same direction. Scientific breakthroughs remain essential, but they’re one element in a much larger ecosystem — regulatory clarity, sustainable investment, scalable manufacturing, reimbursement, adoption, and equitable access all determine whether a discovery ultimately creates value.

Hahn sees no shortage of scientific ambition today — cell therapies, radiopharmaceuticals, gene editing, AI, and precision medicine are all expanding what’s possible. The challenge, in his view, is no longer generating innovation but building the systems that turn it into impact: scientists who understand clinical needs, regulators who provide clarity, investors willing to support long timelines, health systems capable of adoption, and policymakers who recognize where incentives are misaligned.

For Hahn, discovery, approval, and commercial success are all necessary milestones — but not the endpoint. A therapy creates value not because it was discovered, funded, or approved, but because it ultimately reaches a patient whose life becomes meaningfully better as a result. After viewing healthcare from nearly every angle, that remains the metric he returns to most.

From FDA Commissioner to biotech CEO, Hahn’s career spans the full innovation pipeline — and reveals where most breakthroughs actually stall. Image: GeneOnline

Author

Bernice Lottering